Why elevated FSH may predict bone loss years before menopause, and what clinicians can do about it.

Written by: Dr. Douglas Lucas, DO

Founder, The OsteoCollective · Guest Author

Reviewed by Dr. Deanna Minich, PhD, MS, CNS, FMCP, FACN

Each doubling of FSH during the menopause transition is associated with a 39% greater risk of significant lumbar spine bone loss within a year, a stronger signal than estradiol provides, and one that can appear years before the last menstrual period [1].

Most clinicians know to think about bone health after menopause. However, emerging research suggests rising follicle-stimulating hormone (FSH) levels during perimenopause may signal skeletal changes years before significant declines in estradiol occur. This challenges the traditional estrogen-centric view of bone health and raises an important question: should we be assessing bone loss risk earlier, and are there additional hormonal signals worth considering?

Bone Loss Starts Before the Final Menstrual Period

The prevailing narrative places significant emphasis on bone loss during the postmenopausal years. However, bone loss accelerates during perimenopause, representing a vulnerable period for the skeletal system [2,3].

Despite the traditional estrogen-centric view of bone health, estradiol levels fluctuate during perimenopause, and at times, become significantly elevated prior to the final menstrual period [4]. Accelerated bone loss has been observed prior to estradiol decline, suggesting that other factors are influencing skeletal changes [5,6]. Research suggests that FSH may influence bone health independently of estradiol by promoting resorption, or bone breakdown [7].

Even so, FSH is unlikely to act in isolation. Bone remodeling reflects the integrated actions of multiple endocrine signals, including progesterone, which supports osteoblast differentiation and bone formation; testosterone, which helps preserve bone mass through anabolic effects on both bone and skeletal muscle; and melatonin, which influences circadian regulation of bone remodeling by promoting osteoblast activity and suppressing osteoclast function. These findings reinforce the concept that skeletal aging during menopause is a whole-endocrine adaptation rather than simply a consequence of declining estrogen.

"One of the biggest misconceptions in bone health is that we wait until menopause to become concerned about bone loss. As I’ve been discussing for years, the emerging FSH literature suggests the skeleton may be signaling increased vulnerability years earlier, creating an opportunity to identify risk and intervene before substantial bone loss has occurred."  - Dr. Douglas Lucas, DO

The FSH–Osteoclast Pathway: A Mechanism Worth Knowing

FSH receptors (FSHR) are expressed on osteoclast precursors and mature osteoclasts, which are the cells responsible for bone resorption [7]. They are not expressed on osteoblasts, the cells that build bone, however. This receptor localization has functional consequences.

Although osteoclast-mediated resorption is a normal and essential component of bone remodeling, skeletal health depends on maintaining equilibrium between bone resorption and bone formation. When osteoclastic activity exceeds osteoblastic activity, the result is progressive bone loss. Mechanistically, FSH is shown to activate osteoclastogenic signaling cascades, which promotes osteoclast differentiation, activity, and survival [7,8]. FSH also upregulates cytokines that support osteoclast formation [9,10] and facilitates the formation of resorption compartments on bone [7,11,12].  

In a human cell study, FSH stimulated RANK expression (a central mediator of osteoclast differentiation) in a dose-dependent manner, with the strongest effect seen at FSH concentrations typical of perimenopause, with diminishing effects at higher concentrations typical of postmenopause [13]. The perimenopause-range dose-response suggests the skeleton may be most responsive to FSH during the transitional years when FSH is actively rising.

Understanding the dual hormonal effects of FSH and estradiol on bone cells may help explain why bone loss accelerates during perimenopause. Recognizing the unique role of FSH in bone biology can help guide screening for skeletal changes in midlife.

Why Bone Density Changes May Precede Estrogen Decline

FSH and estrogen both influence bone remodeling. Whereas FSH acts on osteoclasts, estrogen acts on both osteoclasts and osteoblasts, supporting bone resorption and formation, respectively [7]. Both hormones change in perimenopause, but FSH does not simply mirror estradiol. FSH levels rise approximately six years before the final menstrual period. This may help to maintain estradiol levels, which remain relatively stable until late perimenopause [14,15]. In some instances, estradiol levels even increase before the final menstrual period [4].

This timing is clinically significant because it suggests a greater role for FSH in midlife skeletal changes. Research suggests that FSH may contribute to changes in bone mineral density (BMD) independently of estradiol [13].

SWAN data show that in pre- and perimenopausal women, each doubling of FSH was associated with a 39% greater risk of significant lumbar spine bone loss [1]. This was a stronger association than that for estradiol, which demonstrated a 10% greater risk per halving. Risk at the femoral neck still favored increasing FSH over declining estradiol, though the difference in risk was less pronounced than that of the lumbar spine.

These site-specific differences may be due to differences in bone microarchitecture [16,17]. It’s suggested that FSH preferentially affects trabecular bone, which is more so found in the lumbar spine compared to the femoral neck [18,19].

Despite consistent associations between FSH and skeletal changes during the menopausal transition, the association is lost in postmenopause, approximately 2 years after the final menstrual period and thereafter [6]. Nonetheless, a cross-sectional study further suggests that FSH may mediate approximately 70% of the observed association between estradiol and BMD in postmenopausal women [20]. This reflects the complex relationship between estradiol and FSH, as well as the need for future research that teases apart their individual effects. Not to mention progesterone, testosterone, cortisol, melatonin and other hormones impact on bone density. For the latest from our medical team on supporting the entire endocrine system and hormones through menopause there is our 20 module course here.

Clinical Assessment: A Layered Approach

Rather than viewing hormones in isolation, a layered approach that incorporates FSH dynamics, individual physiology, and risk factors can support a comprehensive evaluation of skeletal health.

It’s worth noting that most research examining FSH and skeletal health has focused on BMD measured by dual-energy X-ray absorptiometry (DEXA) scans [21,22]. BMD is an important indicator of fracture risk, but it does not fully capture other critical skeletal factors that influence the flexibility, resilience, and structural integrity of bone. Current FSH-bone associations should be read with that limitation in mind; advanced imaging and bone-quality biomarkers may eventually clarify FSH's broader skeletal role.

Alternative imaging methods, such as Radiofrequency Echographic Multi Spectrometry (REMS), may improve access to accurate and, as needed, more frequent bone health assessment [23]. By using ultrasound technology, REMS directly assesses bone mineral density and bone microarchitecture at the femoral neck and lumbar spine. It has demonstrated sensitivity and specificity exceeding 90% at both areas in postmenopausal women undergoing osteoporosis screening [23,24]

Still, FSH may serve as an indirect marker of declining ovarian function, and in some contexts, a more reliable predictor of skeletal change than estradiol alone [9,25].

"Bone health has never been about a single hormone or a single DEXA scan. The future of skeletal assessment lies in integrating hormone dynamics like FSH, imaging, bone quality, lifestyle, nutrition, and metabolic health to better understand who is truly at risk and when intervention can have the greatest impact."   - Dr. Douglas Lucas, DO

FSH Testing: Timing, Trend, and Trajectory

Because FSH levels can fluctuate considerably during perimenopause, periodic assessments that capture trends and trajectories may provide more meaningful clinical insights than a single measurement.

FSH is normally measured in the early follicular phase (days 2 to 5) [26]. IIn women experiencing irregular cycles in perimenopause, timing can become tricky. A practical approach is testing whenever the patient can identify the start of bleeding, though in cycles that are too irregular, random FSH testing becomes the only practical option. Nevertheless, SWAN data show that single FSH measurements outside of the ideal follicular window can still be adequate for identifying at risk women [1].

Serum FSH is the most common assessment method, though at-home urinary FSH assessment is becoming increasingly available and may be a practical way to look at sequential measurements within a month or even month to month.

Stage-Dependent Thresholds

Within the conventional testing model, clinicians often focus on whether a laboratory value falls within or outside a reference range. Yet, endocrine aging is dynamic. A single FSH measurement offers only a snapshot of a continuously evolving physiological process. FSH levels fluctuate throughout the menstrual cycle and become increasingly variable during perimenopause [23,25].

Consistent with a functional testing approach, examining sequential changes over time may provide more context than a single result. The overall pattern of FSH change—and potentially the rate at which those changes occur—may reveal upstream endocrine shifts at the level of the pituitary gland even when values remain within conventional reference intervals.

The FSH trajectory, which describes the rate of change over time, may provide clinical insight. Longitudinal research suggests that women with a high FSH trajectory show greater declines in bone mineral density [33] and more severe hot flashes [34] than those with a low FSH trajectory.

This pattern-based approach stresses understanding the direction and pace of physiological change rather than relying only on static laboratory thresholds.

A modestly elevated FSH level may help initiate proactive care, such as early BMD scans, risk factor review, or dietary and lifestyle changes, rather than a diagnosis in itself.

Interpreting FSH in Context

FSH is best interpreted with context. The fuller picture includes menstrual cycle history, estradiol levels, FSH trend and trajectory, symptom burden, bone turnover markers, and known risk factors.  
It’s important to note that low-weight women (BMI <20 kg/m2) are at an increased risk of skeletal changes in menopause, yet they may present with FSH levels below the diagnostic threshold for menopause [28-30]. FSH alone can underestimate risk in this population, and body composition should factor into screening decisions independent of FSH.

Nutritional and Lifestyle Strategies to Preserve Skeletal Health

Encourage a Plant-Rich Diet. Diets rich in fruits, vegetables, and healthy fats from foods like olive oil, such as the Mediterranean diet, can help maintain healthy bones [31,32]. This style of eating supports inflammatory balance in the body, which is associated with better bone mineral density.

Consider Protein Intake. Plant and animal proteins, combined with exercise, help maintain muscle mass, which supports bone health and balance [33]. Concerns that higher protein intake may increase urinary calcium losses have been debated. However, more recent research has only shown a negative influence on bone in those on bed rest. A higher protein intake has also been associated with higher bone mineral density in older women [34].

Ensure Adequate Micronutrient Status. Ensure adequate levels of micronutrients, particularly vitamin D, vitamin K [35], and calcium, for bone health [36]. Calcium requirements in peri- and post menopause are 1000 and 1200 mg/day, respectively; however, an intentional and balanced diet can likely meet calcium requirements and is preferred over regular supplementation, unless a deficiency exists [37]. Despite lower iron needs in postmenopause, low intake remains common and can contribute to low energy levels, which may make bone-supportive exercise more challenging [36].

Support Endocrine Function with Targeted Supplements. A systems-based approach to menopause recognizes that supporting endocrine health extends beyond replacing or suppressing a single hormone. Clinical research on FemmenessencePRO™ has demonstrated significant support for the hypothalamic-pituitary-thyroid-adrenal-ovarian (HPTAO) axis, with favorable effects on endocrine biomarkers, including FSH and estradiol, together with improvements in menopausal symptoms. Complementary nutrients that support bone remodeling, circadian regulation, metabolic health, and stress physiology, such as vitamin D, vitamin K₂, magnesium, omega-3 fatty acids, and melatonin, may further optimize endocrine resilience. Together, these interventions support the body's integrated hormonal network rather than focusing on a single endocrine pathway.

Discuss Strength Training. Perimenopause represents a pivotal time for exercise interventions to support bone [38]. Strength training and impact exercises support bone health by providing high mechanical loads that strengthen bone structure [39]. Though higher-intensity exercise is often recommended, other types of exercise for bone health include walking [40], Pilates, Tai Chi, Qigong, and yoga [41]. 

Manage Stress. Whether physical or emotional, stress is known to disrupt most systems in our body, including the skeleton. One study describes an inverse association between bone mineral density and cortisol levels in early postmenopausal women [42]. Even modestly elevated cortisol may affect the resorptive capacity of bone and influence fracture risk [43].

For practitioners, the clinical takeaway is timing: tracking FSH trends during perimenopause, rather than waiting for a postmenopausal diagnosis, opens a window for proactive bone density screening and early lifestyle intervention.

Dr. Douglas Lucas, DO

Founder, The OsteoCollective

Double board-certified orthopedic surgeon and longevity physician. After years in traditional orthopedic practice, he stepped away from a system that waits for bones to break before taking action, and shifted his focus to prevention, optimization, and healthspan. His work centers on the idea that bone health is not a geriatric diagnosis but a biomarker of longevity, resilience, and overall health.

Founder of The OsteoCollective, an international online community where thousands of women and men have worked to reverse osteoporosis and improve bone health. As Head of Longevity at LifeMD, he leads both the women's and men's health verticals, helping shape proactive care models that integrate hormones, lifestyle, and long-term health optimization across midlife and beyond.

Host of The Dr. Doug Show: Bones, Hormones & Healthspan and Health 3.0. Author of two Amazon best-selling books. A sought-after speaker and media guest on osteoporosis prevention and reversal, hormone optimization, sexual health, metabolic resilience, and strength training for longevity.

References

1. Shieh A, Greendale GA, Cauley JA, Karvonen-Gutierrez C, Crandall CJ, Karlamangla AS. J Bone Miner Res. 2019;34(12):2246-2253. doi:10.1002/jbmr.3856
2. Neer RM; SWAN Investigators. Ann N Y Acad Sci. 2010;1192:66-71. doi:10.1111/j.1749-6632.2009.05233.x
3. Ho-Pham LT, Nguyen HG, Nguyen-Pham SQ, Hoang DK, Tran TS, Nguyen TV. Osteoporos Int. 2023;34(8):1381-1387. doi:10.1007/s00198-023-06757-z
4. Tepper PG, Randolph JF Jr, McConnell DS, et al. J Clin Endocrinol Metab. 2012;97(8):2872-2880. doi:10.1210/jc.2012-1422
5. Burger HG, Dudley EC, Robertson DM, Dennerstein L. Recent Prog Horm Res. 2002;57:257-275. doi:10.1210/rp.57.1.257
6. Crandall CJ, Tseng CH, Karlamangla AS, et al. J Clin Endocrinol Metab. 2013;98(4):E654-E663. doi:10.1210/jc.2012-3651
7. Chin KY. Int J Med Sci. 2018;15(12):1373-1383. Published 2018 Sep 7. doi:10.7150/ijms.26571
8. Sun L, Peng Y, Sharrow AC, et al. Cell. 2006;125(2):247-260. doi:10.1016/j.cell.2006.01.051
9. Jugulytė N, Bartkevičienė D. Endocrines. 2025; 6(4):54. https://doi.org/10.3390/endocrines6040054
10. Zhou P, Zheng T, Zhao B. Bone. 2022;164:116540. doi:10.1016/j.bone.2022.116540
11. Sun L, Zhang Z, Zhu LL, et al. Biochem Biophys Res Commun. 2010;394(1):6-11. doi:10.1016/j.bbrc.2010.02.113
12. Han G, Zuo J, Holliday LS. Biomolecules. 2019;9(1):17. Published 2019 Jan 9. doi:10.3390/biom9010017
13. Cannon JG, Kraj B, Sloan G. Cytokine. 2011;53(2):141-144. doi:10.1016/j.cyto.2010.11.011
14. Randolph JF Jr, Zheng H, Sowers MR, et al. J Clin Endocrinol Metab. 2011;96(3):746-754. doi:10.1210/jc.2010-1746
15. Delamater L, Santoro N. Clin Obstet Gynecol. 2018;61(3):419-432. doi:10.1097/GRF.0000000000000389
16. Ramírez Stieben LA, Brun LR, Pustilnik E, et al. Calcif Tissue Int. 2025;116(1):137. Published 2025 Dec 1. doi:10.1007/s00223-025-01450-1
17. Sowers MR, Zheng H, Jannausch ML, et al. J Clin Endocrinol Metab. 2010;95(5):2155-2162. doi:10.1210/jc.2009-0659
18. Khosla S, Riggs BL, Robb RA, et al. J Clin Endocrinol Metab. 2005;90(9):5096-5103. doi:10.1210/jc.2005-0396
19. Zaidi M, Blair HC, Iqbal J, et al. Ann N Y Acad Sci. 2007;1116:376-382. doi:10.1196/annals.1402.056
20. Mattick LJ, Bea JW, Hovey KM, et al. Osteoporos Int. 2023;34(4):693-701. doi:10.1007/s00198-023-06676-z
21. Choksi P, Jepsen KJ, Clines GA. Clin Diabetes Endocrinol. 2018;4:12. Published 2018 May 29. doi:10.1186/s40842-018-0062-7
22. Asadipooya K, Greene LW. Front Endocrinol (Lausanne). 2026;17:1768509. Published 2026 Mar 9. doi:10.3389/fendo.2026.1768509
23. Fuggle NR, Reginster JY, Al-Daghri N, et al. Aging Clin Exp Res. 2024;36(1):135. Published 2024 Jun 21. doi:10.1007/s40520-024-02784-w
24. Di Paola M, Gatti D, Viapiana O, et al. Osteoporos Int. 2019;30(2):391-402. doi:10.1007/s00198-018-4686-3
25. Sowers MR, Finkelstein JS, Ettinger B, et al. Osteoporos Int. 2003;14(1):44-52. doi:10.1007/s00198-002-1307-x
26. Testing and interpreting measures of Ovarian Reserve: A committee opinion. American Society for Reproductive Medicine. Accessed July 20, 2026. https://www.asrm.org/practice-guidance/practice-committee-documents/testing-and-interpreting-measures-of-ovarian-reserve-a-committee-opinion-2020/.
27. İncebiyik M, Hilali NG, Er Y, et al. Medicine (Baltimore). 2026;105(13):e48162. doi:10.1097/MD.0000000000048162
28. Stockman SL, Ayinon CM, Nawash B, et al. Climacteric. Published online March 16, 2026. doi:10.1080/13697137.2026.2631509
29. Asomaning K, Bertone-Johnson ER, Nasca PC, Hooven F, Pekow PS. J Womens Health (Larchmt). 2006;15(9):1028-1034. doi:10.1089/jwh.2006.15.1028
30. Wu SF, Du XJ. Med Sci Monit. 2016;22:145-151. Published 2016 Jan 14. doi:10.12659/msm.895512
31. Liu Z, Jian H, Peng Z, Xiong S, Zhang Z. Front Nutr. 2025;12:1508127. Published 2025 Jan 29. doi:10.3389/fnut.2025.1508127
32. Quattrini S, Pampaloni B, Gronchi G, Giusti F, Brandi ML. Nutrients. 2021;13(2):531. Published 2021 Feb 6. doi:10.3390/nu13020531
33. Kędzia G, Woźniak M, Samborski W, Grygiel-Górniak B. Nutrients. 2023;15(21):4581. Published 2023 Oct 28. doi:10.3390/nu15214581
34. Weaver AA, Tooze JA, Cauley JA, et al.J Gerontol A Biol Sci Med Sci. 2021;76(12):2213-2222. doi:10.1093/gerona/glab068
35. Aaseth JO, Finnes TE, Askim M, Alexander J. Nutrients. 2024;16(15):2420. Published 2024 Jul 25. doi:10.3390/nu16152420
36. Liu YC, Guo ZQ. Front Nutr. 2025;12:1702105. Published 2025 Dec 15. doi:10.3389/fnut.2025.1702105
37. Erdélyi A, Pálfi E, Tűű L, et al. Nutrients. 2023;16(1):27. Published 2023 Dec 21. doi:10.3390/nu16010027
38. Karlamangla AS, Burnett-Bowie SM, Crandall CJ. Obstet Gynecol Clin North Am. 2018;45(4):695-708. doi:10.1016/j.ogc.2018.07.012
39. Manaye S, Cheran K, Murthy C, et al. Cureus. 2023;15(2):e34644. Published 2023 Feb 5. doi:10.7759/cureus.34644
40. Yamazaki S, Ichimura S, Iwamoto J, Takeda T, Toyama Y. J Bone Miner Metab. 2004;22(5):500-508. doi:10.1007/s00774-004-0514-2
41. Xu H, Liu J, Li P, Liang Y. Menopause. 2024;31(5):457-467. doi:10.1097/GME.0000000000002336
42. Osella G, Ventura M, Ardito A, et al. Eur J Endocrinol. 2012;166(5):855-860. doi:10.1530/EJE-11-0957
43. Chiodini I, Torlontano M, Carnevale V, Trischitta V, Scillitani A. J Endocrinol Invest. 2008;31(3):267-276. doi:10.1007/BF03345601